Tryp Therapeutics Inc.

Upcoming Events

Nov 8 - Nov 9, 2021

Microdose: Wonderland Miami Conference


Past Events

Sep 21 - Sep 23, 2021

Tryp Therapeutics To Present at Oppenheimer Fall Healthcare Summit

Sep 13 - Sep 15, 2021

H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Virtual
Aug 10 - Aug 12, 2021

TRYP THERAPEUTICS TO PRESENT AT THE CANACCORD ANNUAL GROWTH CONFERENCE

Jul 29 - Jul 29, 2021

Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021

San Diego, California--(Newsfile Corp. - July 15, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host their Q3 Investor Day on July 29, 2021 at 9:00 a.m. PDT.

The event will include a presentation by Tryp's management team to discuss updates on its Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program as well as upcoming milestones for 2021 and beyond. The presentation will be followed with a Q&A session including Greg McKee, Chairman and Chief Executive Officer; Luke Hayes, Chief Financial Officer; and Jim Gilligan, Ph.D., President and Chief Science Officer. A replay of the event will be available for 30 days following the event, and available on our website.

"I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida," commented Greg McKee, Chairman and CEO of Tryp. "The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders."

Webinar Details:

When: Thursday, July 29th, 2021
Time: 9:00 a.m. PDT
Please Register HERE

Please also sign up on Tryp's website to receive updates from the Company and information on future investor events.

For any questions about the event, please contact us at:
T: 1-833-811-TRYP (8797)
E: investors@tryptherapeutics.com
W: www.tryptherapeutics.com

 

Jul 13 - Jul 14, 2021

TRYP THERAPEUTICS TO PRESENT AT THE LADENBURG THALMANN 2021 HEALTHCARE CONFERENCE

San Diego, California--(Newsfile Corp. - June 8, 2021) -  Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually on July 13 and 14. Greg McKee, Chairman and CEO; Jim Gilligan, President and Chief Science Officer; and Luke Hayes, CFO, will provide an overview of Tryp's business and its pipeline followed by a brief analyst-led fireside chat.

Details of the presentation are as follows:

Date: Tuesday, July 13, 2021
Time: 3:00 - 3:25 p.m. EDT
Location: Virtual
Replay: Ladenburg Thalmann 2021 Healthcare Conference

Jul 7 - Jul 8, 2021

Tryp Therapeutics to Present at the Psyched 21 Conference

Tryp Therapeutics is pleased to announce that it is presenting at the Psyched 21 Conference being held virtually from July 6th - 15th.  

Greg McKee, Chairman and CEO, is leading a panel discussion on the use of psychedelic drug compounds to treat neuropathic pain and on the future of research and development activities in psychedelics.  The panel includes the following participants: 

  • Greg McKee, Chairman and CEO, Tryp Therapeutics
  • Jim Gilligan, Ph.D., President and Chief Science Officer, Tryp Therapeutics 
  • Joel Castellanos, M.D., Associate Professor, UC San Diego Department of Anesthesiology 
  • Kevin Boehnke, Ph.D., Research Investigator, University of Michigan Department of Anesthesiology 

The Psyched 21 Conference is the most comprehensive and largest psychedelics conference in the industry with 10 days of engaging content from around the world. Tryp Therapeutics is pleased to announce that Greg McKee sat down with Psyched 21 Founder, Marik Hazan, which you can view HERE, as well as is leading the Panel on psychedelics and pain, which you can view at the link below. 

Watch Panel

Registration is FREE:

Date: July 6th  - 15th

Location: Virtual

Registration: Psyched 21 Conference

 

Jul 7 - Jul 7, 2021

TRYP THERAPEUTICS TO SPEAK & PRESENT AT THE PSYCHED INVESTOR SUMMIT

Jun 22 - Jun 23, 2021

TRYP THERAPEUTICS TO PRESENT AT THE PSYCHEDELIC OPPORTUNITY SUMMIT

Jun 17 - Jun 17, 2021

TRYP THERAPEUTICS TO PRESENT AT THE H.C. WAINWRIGHT PSYCHEDELICS CONFERENCE

Details of the presentation are as follows:

 

Date:                Thursday, June 17th, 2021

Time:                Tryp’s presentation will be available to access beginning at 7:00 a.m. EDT

Registration:   https://hcwevents.com/psychedelics/

Feb 24 - Feb 24, 2021

TRYP THERAPEUTICS TO PRESENT AT THE STIFEL GMP HEALTHCARE CONFERENCE

La Jolla, California - February 24, 2021 -  Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today the company has been invited to present at the Stifel GMP Healthcare Conference: Healthcare Psychedelics: Addressing the Global Mental Health Crisis.

Commencing on March 11, 2021, the virtual conference will host a series of in-depth presentations with leading industry experts who will discuss how their companies are impacting and shaping the future of mental health care. 

Details for Tryp’s presentation include:

Date:                     March 11, 2021

Time:                    10:40 – 11:10 am EST 

Participants:        Tryp Therapeutics Inc. | Jim Kuo, CEO

Feb 3 - Feb 4, 2021

Canaccord Psychedelic Investment Conference

Jan 26 - Jan 28, 2021

EDISON Global Healthcare Conference

Tryp Therapeutics, a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the EDISON Global Heathcare Conference. 

Please sign up to receive updates